| Genetic aberration |
Malignancy |
Therapy |
Aberration conveys |
| KRAS mutation |
CRC |
Cetuximab/ Panitumumab [5] |
Resistance |
| BRAF mutation |
CRC |
Cetuximab/ Panitumumab [5] |
Resistance |
| EGFR mutation |
NSCLC |
Erlotinib/Gefitinib [7] |
Sensitivity |
| EML4_ALK translocation |
NSCLC |
Crizotinib [8] |
Sensitivity |
| BRAF mutation |
melanoma |
Vemurafenib [9] |
Sensitivity |
| cKIT mutation or amplification |
melanoma |
Imatinib/Sumitinib [10] |
|
| BCR_ABL translocation |
CML |
Imatinib/Dasatinib [11] |
Sensitivity |
| HER2 amplification |
breast cancer |
Transtuzumab [12] |
Sensitivity |
|
